The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

From condemning the Jan. 6 Capitol riots to helping fund the President-elect’s impending inauguration, recent years have seen ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

A patient-led study examines the potential of extended Paxlovid courses for Long COVID relief, documenting varied outcomes ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...